Previous Article | Next Article ![]()
Journal of Clinical Microbiology, February 2008, p. 443-446, Vol. 46, No. 2
0095-1137/08/$08.00+0 doi:10.1128/JCM.01986-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Shelley S. Magill,1,2,
Cletus P. Kurtzman,3
Mark J. Fiandaca,4 and
William G. Merz1*
Departments of Pathology,1 Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland,2 Microbial Genomics and Bioprocessing Research Unit, National Center for Agricultural Utilization Research, Agricultural Research Service, U.S. Department of Agriculture, Peoria, Illinois,3 AdvanDx, Inc., Woburn, Massachusetts4
Received 9 October 2007/ Returned for modification 1 November 2007/ Accepted 28 November 2007
Molecular taxonomic studies have revealed new Candida species among phenotypically delineated species, the best example being Candida dubliniensis. This study was designed to determine the occurrence of two new molecularly defined species, Candida bracarensis and Candida nivariensis, which are closely related to and identified as Candida glabrata by phenotypic assays. A total of 137 recent clinical isolates of C. glabrata identified by phenotypic characteristics was tested with C. bracarensis and C. nivariensis species-specific peptide nucleic acid fluorescence in situ hybridization probes. Three of 137 (2.2%) isolates were positive with the C. bracarensis probe, whereas the control strain, but none of the clinical isolates, was positive with the C. nivariensis probe. D1/D2 sequencing confirmed the identification of the three isolates as representing C. bracarensis. Clinically, one C. bracarensis isolate was recovered from a presumed infection, a polymicrobial pelvic abscess in a patient with perforated diverticulitis. The other two isolates were recovered from two adult oncology patients who were only colonized. C. bracarensis was white on CHROMagar Candida, had variable API-20C patterns that overlapped with C. nivariensis and some C. glabrata isolates, and had variable results with a rapid trehalose assay. Interestingly, an isolate from one of the colonized oncology patients was resistant to fluconazole, itraconazole, voriconazole, and posaconazole in vitro. In summary, C. bracarensis was detected among clinical isolates of C. glabrata, while C. nivariensis was not. One C. bracarensis isolate causing a presumed deep infection was recovered, and another isolate was azole resistant. Whether clinical laboratories should identify C. bracarensis will require more data.
Published ahead of print on 12 December 2007.
Present address: Walter Reed Army Medical Center, 6900 Georgia Ave. NW, Washington, DC 20307.
Present address: Mycotic Diseases Branch, Division of Foodborne, Bacterial, and Mycotic Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop C-09, Atlanta, GA 30333.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»